M&T Bank Corp Buys Shares of 19,261 Qiagen N.V. $QGEN

M&T Bank Corp bought a new stake in shares of Qiagen N.V. (NYSE:QGEN) in the fourth quarter, HoldingsChannel.com reports. The firm bought 19,261 shares of the company’s stock, valued at approximately $866,000.

Other hedge funds have also added to or reduced their stakes in the company. Danske Bank A S purchased a new stake in Qiagen during the 3rd quarter valued at $36,000. Smartleaf Asset Management LLC raised its stake in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after buying an additional 830 shares during the last quarter. Allworth Financial LP raised its stake in Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after buying an additional 256 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Qiagen during the 3rd quarter valued at $64,000. Finally, Jones Financial Companies Lllp increased its position in shares of Qiagen by 64.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock valued at $71,000 after purchasing an additional 628 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on QGEN shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research report on Friday, March 27th. Robert W. Baird set a $43.00 price target on shares of Qiagen and gave the company an “outperform” rating in a research report on Wednesday. UBS Group set a $52.00 price target on shares of Qiagen in a research report on Monday, February 9th. Stifel Nicolaus set a $50.00 price target on shares of Qiagen and gave the stock a “hold” rating in a research report on Friday, February 6th. Finally, Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $47.09.

Key Stories Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Baird upgraded QGEN from “hold” to “strong-buy” and set a $43 price target, providing fresh buy-side support and a near-term bullish catalyst. Baird upgrades Qiagen NV (QGEN)
• Neutral Sentiment: Qiagen announced the date for publication of its 2025 annual financial report — a routine disclosure that reduces uncertainty but is unlikely to change the near-term outlook by itself. Qiagen Sets Date for Publication of 2025 Annual Financial Report
• Neutral Sentiment: JPMorgan cut its price target to $45 (from $60) but retained an “overweight” rating — a mixed signal: lower upside in JPM’s model but continued conviction in medium-term outperformance. Qiagen (NYSE:QGEN) Price Target Lowered to $45.00 at JPMorgan Chase & Co.
• Neutral Sentiment: Citigroup trimmed its target to $38 and moved to a “neutral” rating, narrowing analyst-driven upside expectations and adding to mixed analyst sentiment. Citigroup lowers Qiagen price target
• Negative Sentiment: Levi & Korsinsky announced an investigation into Qiagen over potential fraud claims — a reputational and litigation risk that can weigh on the stock until clarified. Ongoing Investigation into Qiagen N.V. (QGEN)
• Negative Sentiment: After-hours trading reacted negatively to management’s guidance cut tied to weaker-than-expected tuberculosis (TB) test demand — this operational weakness is a direct driver of near-term revenue risk. QGEN stock slumps after-hours on guidance cut tied to weak TB test demand
• Negative Sentiment: Reports note QGEN shares hit multi?year weakness as geopolitical headwinds in the Middle East weighed on Q1 results — an external demand shock that contributed to the recent pullback. Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1

Qiagen Trading Up 2.9%

Shares of QGEN opened at $34.58 on Friday. The firm has a market cap of $7.13 billion, a P/E ratio of 17.15, a price-to-earnings-growth ratio of 1.79 and a beta of 0.79. The company has a 50 day simple moving average of $41.78 and a two-hundred day simple moving average of $46.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. Qiagen N.V. has a 1 year low of $33.17 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. The firm had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities analysts expect that Qiagen N.V. will post 2.44 earnings per share for the current fiscal year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.